Oxacillin (Oxacillin)

Trade Name : OXACILLIN

Baxter Healthcare Corporation

INJECTION, SOLUTION

Strength 1 g/50mL

OXACILLIN SODIUM Penicillin-class Antibacterial [EPC],Penicillins [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Oxacillin (Oxacillin) which is also known as OXACILLIN and Manufactured by Baxter Healthcare Corporation. It is available in strength of 1 g/50mL per ml. Read more

Oxacillin (Oxacillin) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin Injection, USP and other antibacterial drugs, Oxacillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Oxacillin Injection, USP is a sterile injectable product containing oxacillin which is added as oxacillin sodium, a semisynthetic penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid. The chemical name of oxacillin sodium is 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(5-methyl-3-phenyl-4- isoxazolyl)carbonyl]-amino]-7-oxo-, monosodium salt, monohydrate, [2S-(2u03b1,5u03b1,6u00df)]-. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The molecular formula of oxacillin sodium is CHNNaOSu2022HO. The molecular weight is 441.44.
The structural formula of oxacillin sodium is as follows:
Oxacillin Injection, USP is a frozen, iso-osmotic, sterile, nonpyrogenic premixed 50 mL solution containing 1 g or 2 g of oxacillin added as oxacillin sodium. Dextrose, USP has been added to the above dosages to adjust osmolality (approximately 1.5 g and 300 mg as dextrose hydrous to the 1 g and 2 g dosages respectively). Sodium Citrate Hydrous, USP has been added as a buffer (approximately 150 mg and 300 mg to the 1 g and 2 g dosages, respectively). The pH has been adjusted with hydrochloric acid and may have been adjusted with sodium hydroxide. The pH is 6.5 (6.0 to 8.5). The solution is intended for intravenous use after thawing to room temperature.
This GALAXY container (PL 2040) is fabricated from a specially designed multilayer plastic (PL 2040). Solutions are in contact with the polyethylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.

Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43u00a0mcg/mL after 5 minutes with a half-life of 20-30 minutes.
The penicillinase-resistant penicillins bind to serum protein, mainly albumin. The degree of protein binding reported for oxacillin is 94.2% u00b1 2.1%. Reported values vary with the method of study and the investigator.
The penicillinase-resistant penicillins vary in the extent to which they are distributed in the body fluids. With normal doses, insignificant concentrations are found in the cerebrospinal fluid and aqueous humor. All the drugs in this class are found in therapeutic concentrations in the pleural, bile, and amniotic fluids.
The penicillinase-resistant penicillins are rapidly excreted primarily as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for oxacillin is about 0.5 hours. Nonrenal elimination includes hepatic inactivation and excretion in bile.
Probenecid blocks the renal tubular secretion of penicillins. Therefore, the concurrent administration of probenecid prolongs the elimination of oxacillin and, consequently, increases the serum concentration.

Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (See .)
Oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Oxacillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant , therapy should not be continued with oxacillin.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin Injection, USP and other antibacterial drugs, Oxacillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

A history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015 and 0.04 percent. Anaphylactic shock resulting in death has occurred in approximately 0.002 percent of the patients treated. Although anaphylaxis is more frequent following parenteral administration, it has occurred in patients receiving oral penicillins.
When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin.
Clostridium difficilen- C. difficile
C. difficilen- C. difficile
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.

No data

No data

The signs and symptoms of oxacillin overdosage are those described in the section. If signs or symptoms occur, discontinue use of the medication, treat symptomatically, and institute appropriate supportive measures.

Oxacillin Injection, USP supplied as a premixed frozen solution is to be administered as a continuous or intermittent intravenous infusion. The usual dose recommendation is as follows:
This container system may be inappropriate for the dosage requirements for children, infants and neonates. Other dosage forms may be more appropriate.
Bacteriologic studies to determine the causative organisms and their susceptibility to oxacillin should always be performed. Duration of therapy varies with the type of severity of infection as well as the overall condition of the patient; therefore, it should be determined by the clinical and bacteriological response of the patient. In severe staphylococcal infections, therapy with oxacillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. Treatment of endocarditis and osteomyelitis may require a longer duration of therapy.
Concurrent administration of oxacillin and probenecid increases and prolongs serum penicillin levels. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Penicillin-probenecid therapy is generally limited to those infections where very high serum levels of penicillin are necessary.
With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Do not add supplementary medication to Oxacillin Injection, USP.
Store in a freezer capable of maintaining a temperature of -20u00b0C/-4u00b0F or less.

Oxacillin Injection, USP is supplied as a premixed frozen iso-osmotic solution in 50 mL single dose GALAXY plastic containers as follows:
Store at or below -20u00b0C/-4u00b0F. [See ]
Handle frozen product containers with care. Product containers may be fragile in the frozen state.

Baxter and Galaxy are registered trademarks of Baxter International Inc.
Baxter Healthcare Corporation
07-19-00-488
Rev. September 2018

Arrayn- Baxter Logo
1 g
Oxacillin Injection, USP
GALAXY
50 mLn- Iso-osmotic
NDC 0338-1013-41n- Code 2G3538n- Sterile Nonpyrogenic
Each 50 mL contains: Oxacillin Sodium equivalent to 1 g Oxacillin with approx.1.5 g Dextrose Hydrous, USP added to adjust osmolality and 150 mg SodiumCitrate Hydrous, USP added as a buffer. pH adjusted with hydrochloric acid andmay have been adjusted with sodium hydroxide. pH 6.5 (6.0 to 8.5).
Dosage: Intravenously as directed by a physician. See insert.
Cautions: Do not add supplementary medication. Must not be used in seriesconnections. Check for minute leaks and solution clarity.
Rx only.
Do not store above -20u00b0C/-4u00b0F. Thaw at room temperature (25u00b0C/77u00b0F) or underrefrigeration (5u00b0C/41u00b0F). Thawed solution is stable for 21 daysunder refrigeration (5u00b0C/41u00b0F) or 48 hours at room temperature (25u00b0C/77u00b0F).
Do not refreeze.
Baxter and Galaxy are registered trademarks ofBaxter International Inc.n n Deerfield, IL 60015 USAMade in USA
PL 2040 Plastic07-34-63-779
Arrayn- Oxacillin Injection, USPn- Iso-osmoticn- Do not store above -20u00b0C/-4u00b0F. Do not refreeze.
1 gn- Baxter Healthcare Corporation
Thaw at room temperature (25u00b0C/77u00b0F) or under refrigeration (5u00b0C/41u00b0F). Thawed solution is stable for 21 days under refrigeration (5u00b0C/41u00b0F) or 48 hours at roomtemperature (25u00b0C/77u00b0F). n
Handle frozen product containers with care. Product containers may be fragile in the frozen state.
Baxter and Galaxy are registered trademarks of Baxter International Inc.
PL 2040 Plastic07-04-65-182
NDC 0338-1013-41n- Code 2G3538n- *FOR BAR CODE POSITION ONLY
GALAXY
Each 50 mL contains: Oxacillin Sodium equivalent to 1 g Oxacillin with approx. 1.5 g ofDextrose Hydrous, USP added to adjust osmolality and 150 mg Sodium Citrate Hydrous, USPadded as a buffer. pH adjusted with hydrochloric acid and may have been adjusted with sodiumhydroxide. pH 6.5 (6.0 to 8.5).
Dosage: Intravenously as directed by a physician. See insert.
Cautions: Do not add supplementary medication. Must not be used in series connections. Checkfor minute leaks by squeezing thawed bag firmly. If leaks are found, discard bag as sterility maybe impaired. Do not use unless solution is clear. n
Arrayn- Baxter Logo
2 g
Oxacillin Injection, USP
GALAXY
50 mLn- Iso-osmotic
NDC 0338-1015-41n- Code 2G3539n- Sterile Nonpyrogenic
Each 50 mL contains: Oxacillin Sodium equivalent to 2 g Oxacillin with approx.300 mg Dextrose Hydrous, USP added to adjust osmolality and 300 mg SodiumCitrate Hydrous, USP added as a buffer. pH adjusted with hydrochloric acid andmay have been adjusted with sodium hydroxide. pH 6.5 (6.0 to 8.5).
Dosage: Intravenously as directed by a physician. See insert.
Cautions: Do not add supplementary medication. Must not be used in seriesconnections. Check for minute leaks and solution clarity.
Rx only.
Do not store above -20u00b0C/-4u00b0F. Thaw at room temperature (25u00b0C/77u00b0F) or underrefrigeration (5u00b0C/41u00b0F). Thawed solution is stable for 21 daysunder refrigeration (5u00b0C/41u00b0F) or 48 hours at room temperature (25u00b0C/77u00b0F).
Do not refreeze.
Baxter and Galaxy are registered trademarks ofBaxter International Inc.n n Deerfield, IL 60015 USAMade in USA
PL 2040 Plastic07-34-63-780
Arrayn- Oxacillin Injection, USPn- Iso-osmoticn- Do not store above -20u00b0C/-4u00b0F. Do not refreeze.
2 gn- Baxter Healthcare Corporation
Thaw at room temperature (25u00b0C/77u00b0F) or under refrigeration (5u00b0C/41u00b0F). Thawed solution is stable for 21 days under refrigeration (5u00b0C/41u00b0F) or 48 hours at roomtemperature (25u00b0C/77u00b0F). n
Handle frozen product containers with care. Product containers may be fragile in the frozen state.
Baxter and Galaxy are registered trademarks of Baxter International Inc.
PL 2040 Plastic07-04-65-183
NDC 0338-1015-41n- Code 2G3539n- *FOR BAR CODE POSITION ONLY
GALAXY
Each 50 mL contains: Oxacillin Sodium equivalent to 2 g Oxacillin with approx. 1.5 g ofDextrose Hydrous, USP added to adjust osmolality and 300 mg Sodium Citrate Hydrous, USPadded as a buffer. pH adjusted with hydrochloric acid and may have been adjusted with sodiumhydroxide. pH 6.5 (6.0 to 8.5).
Dosage: Intravenously as directed by a physician. See insert.
Cautions: Do not add supplementary medication. Must not be used in series connections. Checkfor minute leaks by squeezing thawed bag firmly. If leaks are found, discard bag as sterility maybe impaired. Do not use unless solution is clear. n

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Oxacillin (Oxacillin)

Trade Name : OXACILLIN

INJECTION, SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Oxacillin (Oxacillin)

Trade Name : OXACILLIN

INJECTION, SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?